Skip Navigation



Annals of Oncology Advance Access published online on October 27, 2006
Annals of Oncology, doi:10.1093/annonc/mdl397
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/2/376    most recent
mdl397v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boleti, E.
Right arrow Articles by Mead, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boleti, E.
Right arrow Articles by Mead, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received August 16, 2006
Revised September 8, 2006
Accepted September 14, 2006

original article

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors

E. Boleti 1 * and G. M. Mead 1

1 Department of Medical Oncology, Southampton General Hospital, CRUK Clinical Centre, Southampton, Hampshire, UK

* To whom correspondence should be addressed.
E. Boleti, E-mail: ekaterini.boleti{at}suht.swest.nhs.uk


  Abstract

Background: We investigated whether administration of full-dose ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy without growth factors, and irrespective of the granulocyte count, caused treatment delays or increased the number of infective episodes, in patients with Hodgkin's lymphoma (HL).

Patients and methods: Thirty-eight patients with confirmed predominantly early-stage HL were treated with ABVD outside clinical trial protocols over a 5-year period on an outpatient basis.

Results: Ninety-five per cent of patients completed their scheduled ABVD regimen without adverse effects despite the development of neutropenia. Anaemia and thrombocytopenia did not present problems. Febrile neutropenia complicated 0.57% of combination chemotherapy injections. No growth factors were used and no dose modifications were carried out apart from the omission of bleomycin in one patient for the last two cycles of treatment due to the development of lung toxicity. All patients are currently disease-free, although three (7.8%) required salvage high-dose therapy (one relapsed and two with refractory disease).

Conclusions: ABVD administration irrespective of granulocyte counts allowed the treatment to be given at full dose without delays or significant number of infective episodes. There was no need for growth factor support, minimising treatment costs. The use of full-dose ABVD irrespective of granulocyte count should be evaluated in future protocols for HL.

Keywords: ABVD; chemotherapy; GCSF; growth factors; Hodgkin lymphoma; neutropenia.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JWatch Oncology and HematologyHome page
Managing Neutropenia During ABVD for Hodgkin Lymphoma
Journal Watch Oncology and Hematology, March 19, 2007; 2007(319): 1 - 1.
[Full Text]

Home page
 ASH Education BookHome page
S. J. Horning
Risk, Cure and Complications in Advanced Hodgkin Disease
Hematology, January 1, 2007; 2007(1): 197 - 203.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.